BC Week In Review | Jul 14, 2014
Company News

Santaris, Servier, miRagen deal

The partners extended by two years to October 2016 a 2011 deal to develop and commercialize microRNA-targeting products for cardiovascular disease. The deal includes miRagen’s preclinical programs targeting microRNA-208 ( miR-208 ) and miR-15/195 , plus an undisclosed...
BC Week In Review | Jun 3, 2013
Company News

miRagen, Santaris, Servier deal

Servier exercised its right to add a third target to a 2011 deal with miRagen to develop and commercialize microRNA-targeting products for cardiovascular disease. Servier's target selection triggered the first undisclosed milestone payment to miRagen....
BioCentury | Nov 7, 2011
Strategy

Servicing CV

While some pharmas have concluded cardiovascular disease is well served by generics and are exiting the space, Servier believes it can grow its CV business by in-licensing novel, first-in-class programs. Last month, Servier agreed to...
BC Week In Review | Oct 24, 2011
Company News

miRagen, Santaris, Servier deal

Servier partnered with miRagen to develop and commercialize microRNA-targeting products for cardiovascular disease. The deal includes miRagen's preclinical programs targeting microRNA-208 ( miR-208 ) and miR-15/195, as well as a cardiovascular microRNA modulator yet to be identified....
BC Extra | Oct 19, 2011
Top Story

Servier, miRagen in cardiovascular deal

Servier (Neuilly-sur-Seine, France) partnered with miRagen Therapeutics Inc. (Boulder, Colo.) to develop and commercialize microRNA-targeting products for cardiovascular disease. The deal includes miRagen's preclinical programs targeting microRNA-208 (miR-208) and miR-15/195, as well as a cardiovascular...
Items per page:
1 - 5 of 5